Evidence map›Paper›PMID 32255426›Full record

ArticleeLife2020

A highly accurate platform for clone-specific mutation discovery enables the study of active mutational processes.

Mohammad KaramiNejadRanjbar, Sahand Sharifzadeh, Nina C Wietek, Mara Artibani, Salma El-Sahhar, Tatjana Sauka-Spengler, Christopher Yau, Volker Tresp, Ahmed A Ahmed

Open access · goldAbstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mohammad KaramiNejadRanjbarWeatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-7770-2065
Sahand SharifzadehLudwig Maximilian University of Munich, Munich, Germany.
Nina C WietekWeatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Mara ArtibaniWeatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Salma El-SahharWeatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Tatjana Sauka-SpenglerWeatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-9289-0263
Christopher YauInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0001-7615-8523
Volker TrespLudwig Maximilian University of Munich, Munich, Germany.
Ahmed A AhmedWeatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-6509-2581
University of Oxford · GBLudwig-Maximilians-Universität München · DESiemens (Germany) · DEUniversity of Birmingham · GB

Funding

U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C, SOOD, ANIL K · 2017 to 2021
$7.9M
National Institute for Health Research IS-BRC-0211-10025NCI NIH HHS P50 CA217685Ovarian Cancer Action HER000762
6 · The paper itself

Abstract

Bulk whole genome sequencing (WGS) enables the analysis of tumor evolution but, because of depth limitations, can only identify old mutational events. The discovery of current mutational processes for predicting the tumor's evolutionary trajectory requires dense sequencing of individual clones or single cells. Such studies, however, are inherently problematic because of the discovery of excessive false positive (FP) mutations when sequencing picogram quantities of DNA. Data pooling to increase the confidence in the discovered mutations, moves the discovery back in the past to a common ancestor. Here we report a robust WGS and analysis pipeline (DigiPico/MutLX) that virtually eliminates all F results while retaining an excellent proportion of true positives. Using our method, we identified, for the first time, a hyper-mutation (kataegis) event in a group of ∼30 cancer cells from a recurrent ovarian carcinoma. This was unidentifiable from the bulk WGS data. Overall, we propose DigiPico/MutLX method as a powerful framework for the identification of clone-specific variants at an unprecedented accuracy.

Indexed as

Genome, HumanMutationFemaleGenetic VariationHumansOvarian NeoplasmsSequence Analysis, DNAWhole Genome Sequencingcancer biologygeneticsgenomicshumanmachine learningvariant callingwhole genome amplified

Identifiers

PMID32255426
PMCPMC7228773
OpenAlexW3015047893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.